Novo Nordisk Overtakes SAP as Europe’s Most Valuable Company

Bloomberg
06/13

Novo Nordisk A/S reclaimed its position as Europe’s most valuable public company, overtaking software developer SAP SE.

Shares in the Danish drugmaker climbed as much as 2.3% on Friday after Novo said it plans to advance its experimental weight management treatment amycretin into late-stage development following feedback from regulatory authorities.

Novo’s market capitalization stood at $365 billion as of 10:20 a.m. in Copenhagen. That compares with $364.3 billion for SAP, according to data compiled by Bloomberg.

Novo has suffered a series of setbacks since reaching a record high in June of last year, including disappointing clinical trial results for its experimental obesity treatments and mounting competition from US rival Eli Lilly & Co. The drugmaker last month decided to replace Chief Executive Officer Lars Fruergaard Jorgensen.

The shares have been boosted this week following a Financial Times report about activist hedge fund Parvus Asset Management building a stake in Novo, hoping to influence the appointment of the drugmaker’s new CEO.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10